Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
Su, JM; Li, MT; He, L; Zhao, DB; Wan, WG; Liu, Y; Xu, JH; Xu, J; Liu, HX; Jiang, LD; Wu, HX; Zuo, XX; Huang, CB; Liu, XM; Li, F; Zhang, ZY; Liu, XY; Dong, LL; Li, TW; Chen, HY; Li, JY; He, DY; Lu, X; Huang, AB; Tao, Y; Wang, YY; Zhang, ZL; Wei, W; Li, XF; Zeng, XF
Zeng, XF (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Dept Rheumatol, Peking Union Med Coll Hosp, 1 Shuaifuyuan, Beijing 100730, Peoples R China.; Zeng, XF (corresponding author), Minist Sci & Technol, Natl Clin Res Ctr Immunol Dis, 1 Shuaifuyuan, Beijing 100730, Peoples R China.; Zeng, XF (corresponding author), Minist Educ, Key Lab Rheumatol & Clin Immunol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
BIODRUGS, 2020; 34 (3): 381
